ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007

Regional Groups: Why 15 Were Not Among Those Funded; Cancer Regional Studies Review Committee Chartered

July 2, 1982

Obit: Fred Rapp, Penn State Dean And Virologist, Dead At 72.

April 6, 2001

Trials Could Start Earlier If Model Contract Language Adopted, NCI and CEO Roundtable Say.

December 12, 2008

Mayer Will Emphasize Rehab Research While Serving On NCAB

May 24, 1991

Sixty CCOPs Could cost $16 Million; DCPC Staff Believes They Can Get It

October 10, 1986